28. 全身性アミロイドーシス ［臨床試験数：212，薬物数：234（DrugBank：72），標的遺伝子数：54，標的パスウェイ数：170］
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||EUCTR2017-002210-31-DE||31/05/2019||24/01/2019||An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly-diagnosed cardiac AL amyloidosis patients with bortezomib-based therapy||A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ReDox||Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plasma cell clone producing light chains (LCs) that undergo conformational changes, aggregate and deposit in tissues in the form of amyloid fibrils. This process causes dysfunction of the organs involved and leads to death if not effectively treated.;Therapeutic area: Not possible to specify||Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo||NULL||Authorised-recruitment may be ongoing or finished|| Female: yes|
|120||Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): no||Canada;Turkey;Germany|
|2||NCT03474458||February 11, 2019||16/3/2018||A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy||A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy||Cardiac AL Amyloidosis||Drug: Doxycycline;Drug: Standard of care therapy||IRCCS Policlinico S. Matteo||NULL||Recruiting||18 Years||N/A||All||120||Phase 2/Phase 3||Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom|
|3||NCT02207556||October 1, 2014||23/7/2014||Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial||Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis (DUAL) Trial: A Phase II Open Label Study of Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain (AL) Amyloidosis||Primary Systemic Amyloidosis||Drug: Doxycycline||Medical College of Wisconsin||NULL||Active, not recruiting||18 Years||N/A||All||32||Phase 2||United States|